Commonly known as Rogaine (brand name), Minoxidil is a topical application that enhances hair growth. Less effective in Male Pattern Baldness than 'Bald patches', Minoxidil is the most commonly used topical hair growth compound.
This page features 32 unique references to scientific papers.
Follow this Page for updates
Usage of minoxidil as a topical formulation in the concentration range of 2-5%, with 5% being slightly better than 2% at promoting hair growth. Although oral supplementation technically aids hair growth, it is not advised due to possible complications with blood pressure.
The Human Effect Matrix looks at human studies (it excludes animal and in vitro studies) to tell you what effects minoxidil has on your body, and how strong these effects are.
|Grade||Level of Evidence|
|Robust research conducted with repeated double-blind clinical trials|
|Multiple studies where at least two are double-blind and placebo controlled|
|Single double-blind study or multiple cohort studies|
|Uncontrolled or observational studies only|
Level of Evidence
? The amount of high quality evidence. The more evidence, the more we can trust the results.
Magnitude of effect
? The direction and size of the supplement's impact on each outcome. Some supplements can have an increasing effect, others have a decreasing effect, and others have no effect.
Consistency of research results
? Scientific research does not always agree. HIGH or VERY HIGH means that most of the scientific research agrees.
|Hair Regrowth||Notable||Very High See all 8 studies|
Table of Contents:
Minoxidil is converted into its active metabolite minoxidil sulphate via the enzyme minoxidil sulfotransferase.
Minoxidil works mostly through prolonging the Anagen phase of hair cells, which promotes their growth. Hair cells go through three phases of growth (Anagen), regression (Catagen) and rest (Telogen), which are cycled through as new follicles replace the older ones with similar looking follicles. Shortened Anagen phases precede hair loss disorders such as Male Pattern Baldness (Androgenic Alopceria) where testosterone and its derivative DHT influence a shortening of Anagen.
The mechanism that is currently investigated for Minoxidil's direct mechanism of action involves ATP sensitive K+ channels. One in vitro study (using organ culture) noted that Minoxidil was able to inhibit the reduction of the Anagen phase induced by Tolbutamide, an ATP sensitive K+ channel blocker, while establishing that follicles experssed these K+ channels, with hetereogeneous distribution for follicle, bulb, and scalp. This study also noted that Minoxidil prolonged anagen only in cultures without select growth factors (insulin, hydrocortisone) and in this scenario Tolbutamide blocked Minoxidil. One of these receptors (Sulfonylurea 2B) is expressed in the dermal papillae cells as well as follicles and may be involved in Minoxidil signalling via adenosine and the A1 receptor.
Another plausible explanation could be blood flow enhancement, where increased blood flow has been noted at 5% topical Minoxidil but not lesser doses.
Finally, it is plausible that Minoxidil works via the immune system. As was indicating in a letter to the editor it was suggested that the stimulation of prostaglandin synthase-1 and subsequent production of PGE(2) may induce hair growth. It should be noted that general hair loss (alopecia areata) appears to be involved with the immune system, where excessive Th1 signalling relative to Th2 is associated with the pathophysiology of Alopecia Areata.
Overtly, a prolongation of the Anagen phase of hair follicles is seen which promotes their growth. The mechanism behind this promotion of Anagen are currently unknown
Androgenic Alopecia is a term for male pattern baldness, a form of hair loss originating from the anterior of the scalp and working along the temples towards the back leaving the sides mostly unaltered. Minoxidil has been noted to be used frequently by persons with Androgenic Alopecia and is associated with subpar adherence in routine daily practise, with one study conducted in two Iranian dermatology clinics noting a 95% voluntary withdrawal rate. The reasons due to perceived side-effects were relatively minimal (13% of dropouts) with the majority of persons either stopping treatment due to low effects (66.5%) or they were simply too bored to apply it (15.3%). Additionally, the success rates of Minoxidil during long-term follow-up (5 years) tends to be lower than shorter trials with around 20-30% of patients remaining satisfied.
A Comparative study specifically looking at Androgenic Alopecia comparing 5% Minoxidil solution (50mg) against 1 (10mg) each twice daily, and it was found that after 24 weeks the increased concentration was able to significantly increase the benefits of hair regrowth when measured at 8, 16, and 24 weeks. The mean change from baseline in the lower dose (in regards to vellous hair count) was 21.2 and in the 5% group 26.4 and similar trends were seen for total hair count, thus the benefits were not 5-fold higher with the higher group although they were significantly higher. This study noted a response rate of 77.4% in the 1% group and 81.1% in the 5% group when looking at slight improvement or better, and 30.8% and 17.1% respectively when looking at moderate improvement (assessed by study investigators).
Minoxidil appears to work on Male Pattern Baldness, but the degree of efficacy and response rate tend to be lower than its effects on general hairloss (Alopecia Areata) as Minoxidil does not work by anti-androgenic means (primary pathology of Male Pattern Baldness)
Short term trials note a response rate above 60% while longer term trials pinpoint it at less than 30%, with the decrease being in part a lack of Minoxidil to sustain hair regrowth but mostly due to voluntary dropout
Application of 1mL of 2% solution (20mg) for 24 weeks is associated with an average increase of 13.2% hair count, with less efficacy in more severe instances of hair loss; the response rate was 56.1%.
Relative to placebo, a foam Minoxidil (5%) for 16 weeks is associated with 70.6% self-reported improvement (6.2% worsening) against 42.4% improvement (19.2% worsening) on placebo. Investigator assessments determined that 38.3% of the Minoxidil group had hair regrowth and 5.2% of placebo, with 'marked' hair regrowth being measured at 7.8% and 0.6%; respectively.
When comparing a 5% solution against a 1% solution, the responses for 'slightly' and 'moderately' improved are 81.1% and 30.8% (5%) against 77.4% and 17.1%, suggesting getting a solution up to 5% is slightly more effective. Response rate of 5% Minoxidil after 12 months of treatment has been noted at 52% in androgenic alopecia, lower than 1mg Finasteride and in females with Alopecia Areata 5% Minoxidil is more effective than 2% when assessed by patients and by nonvellous hair count. Although 5% Minoxidil trends to be more effective than 1-2% at early measurements, most statistically significant differences are seen at 48 weeks although sometimes noted as soon as 8 weeks. One study has noted that, at 48 weeks, that 5% Minoxidil resulted in 45% more hair regrowth when compared against 2% Minoxidil (despite both being more effective than placebo) 
Higher concentrations of Minoxidil up to 5% appear more effective, but despite the more than doubling of the dose (from 2%) they are not twice as effective. Response rates are increased slightly as well as degree of efficacy with the 5% formulations, solution or foam
When Minoxidil usage is ceased, the rates of hair regrowth are normalized and the appearance of balding returns to baseline within 4-6 months. If maintained, the increase in hair regrowth when measured at 2 years is usually an average of 30% more than placebo with 5% trending to be more effective than 2%; this study is relatively low powered.
Minoxidil is a hair loss band-aid, and not a cure; cessation of Minoxidil slowly abolishes the benefits to hair and returns to regular balding patterns
Minoxidil 5% Foam is a new delivery method of Minoxidil, and appears to be effective in persons with androgenic alopecia (male pattern baldness). One study comparing a foam of 5% Minoxidil (once daily application, a cupful delivering 50mg) against twice-daily 2% Minoxidil solution (20mg in each application) in women suffering from alopecia noted that, over the course of 24 weeks, that 5% foam trended towards being more effective than 2% Minoxidil solution and increased hair count by 16.2% while the solution increased it by 13.8%. The foam was rated as significantly better for not interfering with hair styling and with less reported side-effects, response rate was slightly elevated from 56.1% to 67.7%.
Minoxidil foam appears to work with once-daily application, and may be slightly more effective than traditional solutions
When comparing the efficacy of 5% Minoxidil against 1mg Finasteride (oral anti-DHT agent that induces hair growth) in an open-labeled study of Androgenic Alopecia, it was found that after 12 months of application that reponse rate was lower in Minoxidil (52%) than Finasteride (80%) and failed to find significant differences in efficacy of responders, although Finasteride was associated with lower androgen status (DHT) universally and a loss of libido in 15% of subjects.
Minoxidil may be as effective as Finasteride assuming it works (with studies suggesting either no difference or Finasteride being more effective), but response rate to Minoxidil appears to be significantly lower than Finasteride.
Tretinoin is topical All-trans retinoic acid, a potent analogue of Vitamin A. Tretinoin can enhance the skin permeability of Minoxidil approximately 3-fold at 0.05% and itself has some hair regrowth properties, although with less reponse rate than Minoxidil itself.
The addition of Tretinoin at 0.01% solution to a 5% Minoxidil solution appears to make a once-daily application of the 5% solution as effective as a twice-daily solution of Minoxidil without the Tretinoin.
Pyrithione Zinc is an anti-dandruff compound that may aid in hair regrowth, and one comparative study comparing 1% Pyrithione Zinc (Head and Shoulders) against 5% Minoxidil (Rogaine) as well as their combination noted that Minoxidil was more than twice as effective as Pyrithione Zinc and their combination trended towards being better than 5% Minoxidil at 9 weeks, but ended up performing worse than Minoxidil and nonsignificantly different than Zinc Pyrithione when measured at 27 weeks.
Ketoconazole (Nizoral) is a topical application that can reduce the synthesis of testosterone into DHT and reduce the androgenic effects of DHT on male pattern baldness.
One study using a combination of 2% ketoconazole shampoo and 2% Minoxidil noted that the combination was more effective than 2% Minoxidil in isolation and more effective than 1mg Finasteride in isolation, but less effective than the combination of 2% Minoxidil and 1mg Finasteride. A later study in 8 men with Androgenic Alopecia comparing 2% Ketoconazole applied 2-4 times weekly and daily application of Minoxidil noted that Minoxidil was nonsignificantly more effective at inducing hair regrowth.
May have additive or synergistic benefits, but studies on the combination are low powered
A Cochrane systemic review on the efficacy and side-effects of hair loss treatments (for females) noted that, in regards to Minoxidil, that there was no significant difference in side-effects with 1% or 2% but a slightly increased rate of self-reported 'general' side-effects with twice-daily 5% Minoxidil (this review is cited twice independently in Medline). The Risk Ratio was 3.55 with a CI of 1.10-11.47, and the most commonly reported side-effects were pruritus, skin irritation, and dermatitis with a slightly elevated rate of hair growing in places other than the scalp (such as forehead and sideburns).
- Randall VA. Hormonal regulation of hair follicles exhibits a biological paradox. Semin Cell Dev Biol. (2007)
- KLIGMAN AM. The human hair cycle. J Invest Dermatol. (1959)
- Stough D, et al. Psychological effect, pathophysiology, and management of androgenetic alopecia in men. Mayo Clin Proc. (2005)
- Shorter K, et al. Human hair follicles contain two forms of ATP-sensitive potassium channels, only one of which is sensitive to minoxidil. FASEB J. (2008)
- Li M, et al. Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil. J Invest Dermatol. (2001)
- Wester RC, et al. Minoxidil stimulates cutaneous blood flow in human balding scalps: pharmacodynamics measured by laser Doppler velocimetry and photopulse plethysmography. J Invest Dermatol. (1984)
- Namazi MR, Handjani F. An immunologic mechanism for the therapeutic efficacy of minoxidil in alopecia areata. J Drugs Dermatol. (2004)
- Michelet JF, et al. Activation of cytoprotective prostaglandin synthase-1 by minoxidil as a possible explanation for its hair growth-stimulating effect. J Invest Dermatol. (1997)
- Wolf R, et al. Prostaglandin analogs for hair growth: great expectations. Dermatol Online J. (2003)
- Namazi MR. Nitric oxide donors as potential additions to anti-alopecia areata armamentarium. Inflamm Res. (2003)
- Mapar MA, Omidian M. Is topical minoxidil solution effective on androgenetic alopecia in routine daily practice. J Dermatolog Treat. (2007)
- Olsen EA, et al. Five-year follow-up of men with androgenetic alopecia treated with topical minoxidil. J Am Acad Dermatol. (1990)
- Olsen EA, DeLong ER, Weiner MS. Long-term follow-up of men with male pattern baldness treated with topical minoxidil. J Am Acad Dermatol. (1987)
- Tsuboi R, et al. Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men. J Dermatol. (2009)
- Blume-Peytavi U, et al. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol. (2011)
- Olsen EA, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. (2007)
- Arca E, et al. An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia. Dermatology. (2004)
- Lucky AW, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. (2004)
- Olsen EA, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. (2002)
- Price VH, Menefee E, Strauss PC. Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment. J Am Acad Dermatol. (1999)
- Olsen EA, Weiner MS. Topical minoxidil in male pattern baldness: effects of discontinuation of treatment. J Am Acad Dermatol. (1987)
- Tosti A, Camacho-Martinez F, Dawber R. Management of androgenetic alopecia. J Eur Acad Dermatol Venereol. (1999)
- Effect of Oral Finasteride on Serum Androgen Levels and Androgenetic Alopecia in Adult Men.
- Ferry JJ, et al. Influence of tretinoin on the percutaneous absorption of minoxidil from an aqueous topical solution. Clin Pharmacol Ther. (1990)
- Bazzano GS, Terezakis N, Galen W. Topical tretinoin for hair growth promotion. J Am Acad Dermatol. (1986)
- Shin HS, et al. Efficacy of 5% minoxidil versus combined 5% minoxidil and 0.01% tretinoin for male pattern hair loss: a randomized, double-blind, comparative clinical trial. Am J Clin Dermatol. (2007)
- Berger RS, et al. The effects of minoxidil, 1% pyrithione zinc and a combination of both on hair density: a randomized controlled trial. Br J Dermatol. (2003)
- Hugo Perez BS. Ketocazole as an adjunct to finasteride in the treatment of androgenetic alopecia in men. Med Hypotheses. (2004)
- Khandpur S, Suman M, Reddy BS. Comparative efficacy of various treatment regimens for androgenetic alopecia in men. J Dermatol. (2002)
- Piérard-Franchimont C, et al. Ketoconazole shampoo: effect of long-term use in androgenic alopecia. Dermatology. (1998)
- van Zuuren EJ, et al. Interventions for female pattern hair loss. Cochrane Database Syst Rev. (2012)
- van Zuuren EJ, Fedorowicz Z, Carter B. Evidence-based treatments for female pattern hair loss: a summary of a Cochrane systematic review. Br J Dermatol. (2012)
(Common misspellings for Minoxidil include minoxidril, minidil, minoxadil, rogain, minoxadril)